Introduction: Although international clinical practice guidelines recognize a continued role
for menopausal hormone therapy (HT), particularly for symptomatic women< 60 years of age …

Fezolinetant (VEOZAH™) is an oral, small molecule, neurokinin 3 receptor (NK3R)
antagonist, which is being developed by Astellas Pharma Inc. for the treatment of moderate …

Psychiatric diseases are strongly influenced by genetics, but genetically guided treatments
have been slow to develop, and precise molecular mechanisms remain mysterious …

Background: Over 75% of menopausal women experience vasomotor symptoms (VMS),
such as night sweats and hot flashes. Despite the prevalence of these symptoms, there is …

Systematic review and network meta-analysis comparing the ef... : Menopause Systematic
review and network meta-analysis comparing the efficacy of fezolinetant with hormone and …

Potential endocrine-disrupting properties of cyanotoxins, such as microcystin-LR (MC-LR)
and cylindrospermopsin (CYN) are of concern due to their increasing occurrence, the …

This systematic review and meta-analysis investigated the efficacy and safety of fezolinetant
for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with …

Abstract Background & Objective Vasomotor symptoms (VMS) are the most common
symptoms during menopause including hot flushes and night sweats. They are highly …

Menopause represents the physiological transition when a woman's reproductive period
ends associated with a variety of symptoms, including vasomotor symptoms, such as night …

Objective To evaluate the efficacy and safety of fezolinetant for moderate to severe
vasomotor symptoms (VMS) associated with menopause in East Asian women. Methods In …